Episode 1: Inflammation and Heart Attacks: A New Frontier in Prevention with LODOCO
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Episode 1: Inflammation and Heart Attacks: A New Frontier in Prevention with LODOCO
-
Narrated by:
-
By:
About this listen
In this episode of Industry Innovations, host Dr. Peter Jones is joined by Dr. Guy Mintz to explore an exciting advancement in cardiovascular care: LODOCO, a low-dose colchicine developed by Agepha Pharma. Backed by robust clinical trial data, LODOCO is an FDA-approved therapy targeting inflammation as a novel approach to reducing the risk of heart attacks.
Learn how inflammation contributes to cardiovascular events and why this groundbreaking therapy is redefining prevention strategies. Dr. Mintz discusses the science, the data, and the potential impact of LODOCO on clinical practice, offering valuable insights for clinicians committed to improving patient outcomes.
Sponsored by Agepha Pharma
No reviews yet